Cardiotoxic local anesthetics increasingly interact with biomimetic membranes under ischemia-like acidic conditions.
The cardiotoxic effects of local anesthetics increase in cardiac ischemia which is characterized by the tissue pH lowering to 6.5 or less. Apart from the cardiac channel blockade, the membrane interaction has been referred to as another mode of their cardiotoxic action. By using biomimetic membranes, we verified the hypothesis that bupivacaine and lidocaine may increasingly interact with cardiac mitochondrial membranes under ischemia-like acidic conditions. Biomimetic membranes were prepared with different phospholipids and cholesterol to be unilamellar vesicles suspended in buffers of pH 7.4, 6.9, 6.4 or 5.9. Bupivacaine and lidocaine were reacted with the membrane preparations at cardiotoxically relevant concentrations and their membrane interactivities were determined by measuring fluorescence polarization. Both drugs interacted with 100 mol% 1,2-dipalmitoylphosphatidylcholine, peripheral nerve cell-mimetic and cardiomyocyte-mimetic membranes to increase membrane fluidity, although lowering the reaction pH from 7.4 to 5.9 decreased their membrane-fluidizing effects. In cardiomyocyte mitochondria-mimetic membranes containing 20 mol% cardiolipin, however, bupivacaine and lidocaine reversely increased their membrane interactivities at pH 5.9-6.4 compared with pH 7.4. Such increases were greater in anionic phospholipid membranes which consisted of substantial amounts of cardiolipin and phosphatidylserine. Positively charged bupivacaine and lidocaine would form ion-pairs with the negatively charged head-groups of anionic phospholipids under acidic conditions, thereby increasing the induced membrane fluidization. The mitochondrial membrane interactions depending on pH lowering may be, at least in part, responsible for local anesthetic cardiotoxicity enhanced in acidosis associated with cardiac ischemia.
Department of Dental Basic Education, School of Dentistry, Asahi University, Mizuho, Gifu, Japan. hiro@dent.asahi-u.ac.jp
Hironori
H
Tsuchiya
Maki
M
Mizogami
Takahiro
T
Ueno
Kenji
K
Shigemi
D000779:Anesthetics, Local / Q000494:pharmacology*; D002045:Bupivacaine / Q000494:pharmacology*; D002308:Cardiolipins / Q000737:chemistry; D054715:Cardiotoxins / Q000494:pharmacology*; D002462:Cell Membrane / Q000187:drug effects / Q000502:physiology; D020404:Glycerophospholipids / Q000737:chemistry; D006863:Hydrogen-Ion Concentration; D007511:Ischemia; D008012:Lidocaine / Q000494:pharmacology*; D008560:Membrane Fluidity / Q000187:drug effects; D008567:Membranes, Artificial; D008928:Mitochondria / Q000187:drug effects / Q000502:physiology; D010716:Phosphatidylinositols / Q000737:chemistry; D013109:Sphingomyelins / Q000737:chemistry
D000779:Anesthetics, Local; D002308:Cardiolipins; D054715:Cardiotoxins; D020404:Glycerophospholipids; D008567:Membranes, Artificial; D010716:Phosphatidylinositols; D013109:Sphingomyelins; D008012:Lidocaine; D002045:Bupivacaine